the therapy modifications also influenced survival following remission induction : daunorubicin-treated patients , aged 3 years and over , did significantly better than those given doxorubicin ( p = .03 ) , but the opposite was seen in younger children ( p = .06 ) .
C0011015
daunorubicin
C0013089
doxorubicin